Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (2008). „A phase II dose-ranging study of topical resiquimod to treat actinic keratosis”. The British Journal of Dermatology. 159 (1): 205—10. PMID18476957. doi:10.1111/j.1365-2133.2008.08615.x.
Wu JJ, Huang DB, Tyring SK (2004). „Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses”. Antiviral Research. 64 (2): 79—83. PMID15498602. doi:10.1016/j.antiviral.2004.07.002.
Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (2007). „Resiquimod and other immune response modifiers as vaccine adjuvants”. Expert Review of Vaccines. 6 (5): 835—47. PMID17931162. doi:10.1586/14760584.6.5.835.
Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (2009). „TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells”. Immunobiology. 214 (8): 683—91. PMID19249118. doi:10.1016/j.imbio.2008.12.003.
Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (2008). „Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function”. Experimental Biology and Medicine (Maywood, N.J.). 233 (8): 968—79. PMID18480416. doi:10.3181/0802-RM-58.
nih.gov
ncbi.nlm.nih.gov
Szeimies RM, Bichel J, Ortonne JP, Stockfleth E, Lee J, Meng TC (2008). „A phase II dose-ranging study of topical resiquimod to treat actinic keratosis”. The British Journal of Dermatology. 159 (1): 205—10. PMID18476957. doi:10.1111/j.1365-2133.2008.08615.x.
Wu JJ, Huang DB, Tyring SK (2004). „Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses”. Antiviral Research. 64 (2): 79—83. PMID15498602. doi:10.1016/j.antiviral.2004.07.002.
Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP (2007). „Resiquimod and other immune response modifiers as vaccine adjuvants”. Expert Review of Vaccines. 6 (5): 835—47. PMID17931162. doi:10.1586/14760584.6.5.835.
Hurst J, Prinz N, Lorenz M, Bauer S, Chapman J, Lackner KJ, von Landenberg P (2009). „TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells”. Immunobiology. 214 (8): 683—91. PMID19249118. doi:10.1016/j.imbio.2008.12.003.
Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ (2008). „Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function”. Experimental Biology and Medicine (Maywood, N.J.). 233 (8): 968—79. PMID18480416. doi:10.3181/0802-RM-58.